Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Clin Exp Immunol ; 208(3): 301-315, 2022 06 23.
Artículo en Inglés | MEDLINE | ID: mdl-35404420

RESUMEN

Vδ2+ T cells can recognize malignantly transformed cells as well as those infected with mycobacteria. This cross-reactivity supports the idea of using mycobacteria to manipulate Vδ2+ T cells in cancer immunotherapy. To date, therapeutic interventions using Vδ2+ T cells in cancer have involved expanding these cells in or ex vivo using zoledronic acid (ZA). Here, we show that the mycobacterium Bacillus Calmette-Guérin (BCG) also causes Vδ2+ T-cell expansion in vitro and that resulting Vδ2+ cell populations are cytotoxic toward tumour cell lines. We show that both ZA and BCG-expanded Vδ2+ cells effectively killed both Daudi and THP-1 cells. THP-1 cell killing by both ZA and BCG-expanded Vδ2+ cells was enhanced by treatment of targets cells with ZA. Although no difference in cytotoxic activity between ZA- and BCG-expanded Vδ2+ cells was observed, BCG-expanded cells degranulated more and produced a more diverse range of cytokines upon tumour cell recognition compared to ZA-expanded cells. ZA-expanded Vδ2+ cells were shown to upregulate exhaustion marker CD57 to a greater extent than BCG-expanded Vδ2+ cells. Furthermore, ZA expansion was associated with upregulation of inhibitory markers PD-1 and TIM3 in a dose-dependent manner whereas PD-1 expression was not increased following expansion using BCG. Intradermal BCG vaccination of rhesus macaques caused in vivo expansion of Vδ2+ cells. In combination with the aforementioned in vitro data, this finding suggests that BCG treatment could induce expansion of Vδ2+ T cells with enhanced anti-tumour potential compared to ZA treatment and that either ZA or BCG could be used intratumourally as a means to potentiate stronger anti-tumour Vδ2+ T-cell responses.


Asunto(s)
Mycobacterium bovis , Linfocitos T , Animales , Vacuna BCG , Activación de Linfocitos , Macaca mulatta/metabolismo , Receptor de Muerte Celular Programada 1 , Receptores de Antígenos de Linfocitos T gamma-delta/metabolismo , Ácido Zoledrónico/farmacología
2.
J Exp Med ; 192(12): 1841-8, 2000 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-11120780

RESUMEN

Lymphocytes usually differentiate into effector cells within days after antigen exposure, except in germinal centers where terminal differentiation is delayed while somatic hypermutation creates high-affinity antibody mutants. Here we investigate whether arrest of terminal differentiation can be mediated by BCL-6, a transcriptional repressor that is expressed by germinal center B cells and is required for this phase of B cell development. We find that BCL-6 suppresses the differentiation of transformed and primary B cells to plasma cells by inhibiting the signal transducer and activator of transcription 3-dependent expression of the major regulator of plasma cell development, the B lymphocyte-induced maturation protein (Blimp-1). This function of BCL-6 as a repressor of B lymphocyte differentiation may also underlie the association between chromosomal translocations of its gene and B cell lymphomas.


Asunto(s)
Linfocitos B/citología , Diferenciación Celular , Proteínas de Unión al ADN/antagonistas & inhibidores , Proteínas de Unión al ADN/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Transactivadores/antagonistas & inhibidores , Factores de Transcripción/metabolismo , Animales , Linfocitos B/efectos de los fármacos , Linfocitos B/metabolismo , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Citocinas/farmacología , Proteínas de Unión al ADN/genética , Citometría de Flujo , Ratones , Células Plasmáticas/citología , Células Plasmáticas/efectos de los fármacos , Células Plasmáticas/metabolismo , Factor 1 de Unión al Dominio 1 de Regulación Positiva , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-bcl-6 , Proteínas Represoras/metabolismo , Factor de Transcripción STAT3 , Transactivadores/metabolismo , Factores de Transcripción/antagonistas & inhibidores , Factores de Transcripción/genética
3.
Tuberculosis (Edinb) ; 85(1-2): 81-8, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15687031

RESUMEN

SETTING: Dendritic cells (DC) could regulate between the protective and pathogenic immune responses following tuberculous infection. In this paper we investigated if their early infection in the lungs represents a plausible alternative to cross-priming with mycobacterial antigens acquired from infected macrophages. OBJECTIVE: To determine the extent and time course of infection of lung DCs following intranasal inoculation of BALB/c mice with green fluorescent protein (GFP) tagged Bacillus Calmette-Guerin (BCG). RESULTS: A fraction of GFP-BCG infected lung cells were classified as monocytic DCs with the CD11c+IA+33D1+CD8a- phenotype. These cells represented 5-18% of the total GFP+ cells, the bulk of which were macrophages. The infected DCs could be separated by cell size into two fractions with similar cell surface staining properties during the 2-72 h period after infection. An unexpected difference was observed for the time course of infection between DCs and macrophages: DC infection peaked at 48 h followed by decline at 72 h, while the proportion of infected macrophages remained steady during the same period. CONCLUSION: The presented results are direct evidence that monocytic DCs are recruited to the lungs and take up live bacilli within 48 h of intranasal infection with GFP-BCG. This finding is pertinent for the regulation of pulmonary and systemic immune responses and possibly for the dissemination of mycobacterial infection by DCs.


Asunto(s)
Células Dendríticas/inmunología , Pulmón/microbiología , Infecciones por Mycobacterium/inmunología , Administración Intranasal , Animales , Antígenos Bacterianos/inmunología , Antígenos CD/inmunología , Antígenos de Superficie/inmunología , Vacuna BCG/administración & dosificación , Tamaño de la Célula , Proteínas Fluorescentes Verdes , Sustancias Luminiscentes , Pulmón/patología , Macrófagos/inmunología , Ratones , Ratones Endogámicos BALB C , Monocitos/inmunología , Infecciones por Mycobacterium/patología , Factores de Tiempo , Tuberculosis Pulmonar/inmunología , Tuberculosis Pulmonar/patología
4.
Clin Exp Immunol ; 143(3): 467-73, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16487246

RESUMEN

Intranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.


Asunto(s)
Inmunización Pasiva/métodos , Inmunoglobulina A/uso terapéutico , Interferón gamma/uso terapéutico , Tuberculosis Pulmonar/prevención & control , Administración Intranasal , Animales , Anticuerpos Monoclonales/uso terapéutico , Antígenos Bacterianos/inmunología , Células Cultivadas , Recuento de Colonia Microbiana , Quimioterapia Combinada , Femenino , Exposición por Inhalación , Macrófagos Alveolares/inmunología , Macrófagos Alveolares/microbiología , Ratones , Ratones Endogámicos BALB C , Tuberculosis Pulmonar/patología , alfa-Cristalinas/inmunología
5.
Eur J Immunol ; 27(2): 572-5, 1997 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9045933

RESUMEN

Co-ligation of antigen receptor and complement receptor 2 (CD21) in the B cell membrane is important in the immune response to T-dependent antigens. Four CD21 ligands have so far been identified, but only the activated products of the third component of complement (C3) are known to augment the immune response to specific antigens. The most recently discovered ligand for CD21 is CD23. We have generated a CD32+ CD23+ fibroblast cell line which presents a surrogate antigen (anti-IgM) to human tonsil B cells in vitro. Incubation with these cells causes a 10- to 100-fold reduction in the threshold concentration of anti-IgM required for B cell proliferation. Anti-CD19 further enhances the response to antigen and induces proliferation in the absence of anti-IgM. Addition of soluble CD21 totally inhibits the effect of CD23, suggesting that CD21 mediates synergistic signaling by CD23.


Asunto(s)
Linfocitos B/inmunología , Inmunidad/inmunología , Receptores de IgE/análisis , Receptores de IgE/inmunología , Anticuerpos Antiidiotipos/inmunología , Células Cultivadas , Niño , Preescolar , Humanos , Inmunoglobulina M/inmunología , Tonsila Palatina/citología
6.
Clin Chem ; 38(4): 522-5, 1992 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1314719

RESUMEN

We describe a colorimetric assay for glucose determination in human serum, with use of the chromogen 2-amino-4-hydroxybenzenesulfonic acid (AHBS), glucose oxidase, and peroxidase. With this assay, glucose concentrations less than or equal to 27.8 mmol/L can be measured in serum, with a sample/reagent volume ratio as low as 0.0025. The chromogen itself is easily soluble in water and does not require other components for the color change, making the reagent composition less complex. A single working reagent is used, and the reaction is completed within 10 min at 37 degrees C. The absorbance of the yellow reaction product is measured at 415 nm, and a blank sample measurement is not needed. The average analytical recovery of glucose in different human sera was 97.6%, with no significant interference of reducing compounds in serum. The results of the recommended procedure correlated well with those of the phenol/4-aminoantipyrine method of Trinder.


Asunto(s)
Glucemia/análisis , Colorimetría/métodos , Ácidos Sulfanílicos , Compuestos Cromogénicos , Colorimetría/estadística & datos numéricos , Glucosa Oxidasa , Humanos , Indicadores y Reactivos , Peroxidasa , Control de Calidad , Espectrofotometría
7.
Glycoconj J ; 9(1): 39-44, 1992 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1392564

RESUMEN

The gene PHO5 coding for one of the repressible acid phosphatases of the yeast Saccharomyces cerevisiae has been expressed at high efficiency in the baby hamster kidney (BHK) cell line. The expression vector was constructed from PHO5 driven by the human beta-actin promoter and was transfected into BHK cells by the calcium phosphate method. The recombinant APase (r-APase) which was secreted in active form from the cells was estimated by SDS/polyacrylamide gel electrophoresis to have molecular mass M(r) = 62,000, indicating substitution of the polypeptide moiety by 2-3 asparagine-linked glycans. Analysis by sequential lectin affinity chromatography of glycopeptides obtained from r-APase with Pronase showed that the glycans are predominantly of the 2.2.4 triantennary and tetraantennary complex-type. These data suggest that the extensive glycosylation of yeast APase, which contains eight polymannose substituents, is not essential for secretion and expression of enzymatic activity of the transfected gene product.


Asunto(s)
Fosfatasa Ácida/fisiología , Saccharomyces cerevisiae/enzimología , Fosfatasa Ácida/biosíntesis , Fosfatasa Ácida/metabolismo , Animales , Secuencia de Bases , Línea Celular , Cricetinae , Electroforesis en Gel de Poliacrilamida , Vectores Genéticos/genética , Glicopéptidos/análisis , Glicosilación , Datos de Secuencia Molecular , Transformación Genética/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA